Compare Elastic NV (ESTC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Medpace Holdings Inc — how do they compare? Elastic NV trades at $62.34 (market cap $6.47B), while Medpace Holdings Inc trades at $535.24 (market cap $15.11B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Elastic NV's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ESTC | MEDP | |
|---|---|---|
Market Cap | $6.47B | $15.11B |
Sector | Technology | Technology |
52-Week High | $94.47 | $620.59 |
52-Week Low | $43.30 | $308.88 |
Enterprise Value | $5.69B | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.
Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
